Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, mu...

Full description

Bibliographic Details
Main Authors: Grill, Jacques, Massimino, Maura, Bouffet, Eric, Azizi, Amedeo A., McCowage, Geoffrey, Cañete, Adela, Saran, Frank, Le Deley, Marie-Cécile, Varlet, Pascale, Morgan, Paul S., Jaspan, Tim, Jones, Chris, Giangaspero, Felice, Smith, Helen, Garcia, Josep, Elze, Markus C., Rousseau, Raphaël F., Abrey, Lauren, Hargrave, Darren, Vassal, Gilles
Format: Article
Language:English
Published: American Society of Clinical Oncology 2018
Online Access:https://eprints.nottingham.ac.uk/50620/

Internet

https://eprints.nottingham.ac.uk/50620/

Similar Items